Abstract
Our data suggest that PTPN20 may have critical functions in Helicobacter pylori (Hp)-related gastric cancer (GC). Targeting PTPN20 may be a promising way to treat Hp-related GC.
Introduction
Gastric cancer (GC) remains one of the most lethal malignancies globally, with Helicobacter pylori (Hp) infection recognized as its primary environmental trigger. While it is established that Hp drives chronic inflammation leading to oncogenesis, the specific molecular mediators—particularly those involving the innate immune system—remain poorly understood. This study sought to identify genes that are differentially expressed during Hp-related gastric cancer and play a functional role in the body’s innate defense mechanisms, serving as both prognostic biomarkers and potential therapeutic targets.
Methodology
The study employed a comprehensive bioinformatic pipeline to analyze large-scale genomic data from public repositories, including The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO).
Key analytical steps included:
- Differential Expression Analysis: Comparing mRNA levels between normal stomach tissue and GC tissue (with and without Hp infection) using the
limmapackage. - Prognostic Modeling: Utilizing Kaplan-Meier survival curves and Cox regression analysis to predict patient outcomes.
- Immune & Mutational Landscape: Estimating the proportions of 22 immune cell types via
CIBERSORTand analyzing Tumor Mutational Burden (TMB) in relation to gene expression. - ceRNA Network Construction: Building a competing endogenous RNA network to identify regulatory lncRNAs and miRNAs.
Key Results
The analysis identified PTPN20 as a pivotal innate immunity-related gene. Interestingly, while PTPN20 expression is significantly lower in tumor tissues compared to normal tissue, higher levels of the remaining PTPN20 within the tumor group are associated with a significantly worse prognosis.
Prognostic and Diagnostic Power
PTPN20 was identified as a standalone risk factor. High expression was associated with a Hazard Ratio (HR) of 3.62 (p = 0.037) for overall survival. Time-dependent ROC curves demonstrated high accuracy in predicting survival, with an Area Under the Curve (AUC) of 0.943 for 1-year survival.
Immune Correlation and Genomic Instability
PTPN20 expression showed a significant negative correlation with M1 macrophages (r = -0.73), suggesting it may contribute to an "immune-cold" tumor environment that evades immune detection. Furthermore, an inverse relationship was found between PTPN20 and TMB; patients with low PTPN20 expression tended to have higher TMB, a factor often associated with better responses to certain immunotherapies.
Discussion and Future Directions
These findings highlight PTPN20 as a "hub" gene within the innate immune network of Hp-related gastric cancer. The study successfully mapped a regulatory ceRNA network consisting of 7 lncRNAs and 5 miRNAs that control PTPN20 levels.
However, as this study is purely computational, future research must focus on "wet-lab" validation. This includes in vitro and in vivo studies to confirm the physical influence of PTPN20 on Hp-induced oncogenesis and exploring whether targeting PTPN20 can sensitize gastric cancers to existing immunotherapies.
Summary updated